immuno-oncology

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

News

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

The FDA has given accelerated approval to a groundbreaking T cell-based therapy from Adaptimmune for synovial sarcoma, becoming the first new treatment for the rare soft tissue cancer in mo

News

Close-up image of a melanoma on the skin

BioNTech cancer vaccine hits the spot in melanoma

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.

News

Boehringer buys oncology player Nerio in $1.3bn deal

Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a "centrepiece" of its immuno-oncology pipe

News

Immutep mulls filings for LAG-3 drug after new readout

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patient

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

GSK bags sought-after Jemperli okay in endometrial cancer

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

BioNTech cancer vaccine hits the spot in melanoma

Boehringer buys oncology player Nerio in $1.3bn deal

Immutep mulls filings for LAG-3 drug after new readout

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

immuno-oncology

Editor's Picks